Science and Research

Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19

(1) Background: In COVID-19 survivors there is an increased prevalence of pulmonary fibrosis of which the underlying molecular mechanisms are poorly understood; (2) Methods: In this multicentric study, n = 12 patients who succumbed to COVID-19 due to progressive respiratory failure were assigned to an early and late group (death within ≤7 and >7 days of hospitalization, respectively) and compared to n = 11 healthy controls; mRNA and protein expression as well as biological pathway analysis were performed to gain insights into the evolution of pulmonary fibrogenesis in COVID-19; (3) Results: Median duration of hospitalization until death was 3 (IQR25-75, 3-3.75) and 14 (12.5-14) days in the early and late group, respectively. Fifty-eight out of 770 analyzed genes showed a significantly altered expression signature in COVID-19 compared to controls in a time-dependent manner. The entire study group showed an increased expression of BST2 and IL1R1, independent of hospitalization time. In the early group there was increased activity of inflammation-related genes and pathways, while fibrosis-related genes (particularly PDGFRB) and pathways dominated in the late group; (4) Conclusions: After the first week of hospitalization, there is a shift from pro-inflammatory to fibrogenic activity in severe COVID-19. IL1R1 and PDGFRB may serve as potential therapeutic targets in future studies.

  • Kamp, J. C.
  • Neubert, L.
  • Ackermann, M.
  • Stark, H.
  • Werlein, C.
  • Fuge, J.
  • Haverich, A.
  • Tzankov, A.
  • Steinestel, K.
  • Friemann, J.
  • Boor, P.
  • Junker, K.
  • Hoeper, M. M.
  • Welte, T.
  • Laenger, F.
  • Kuehnel, M. P.
  • Jonigk, D. D.

Keywords

  • Aged
  • COVID-19/*genetics/*metabolism/mortality
  • Female
  • Hospital Mortality/trends
  • Hospitalization
  • Humans
  • Lung/pathology
  • Male
  • Middle Aged
  • Pulmonary Fibrosis/metabolism/*pathology
  • Respiratory Insufficiency/pathology
  • SARS-CoV-2/pathogenicity
  • Covid-19
  • SARS-CoV-2
  • inflammation
  • pulmonary fibrosis
Publication details
DOI: 10.3390/ijms23031583
Journal: Int J Mol Sci
Number: 3
Work Type: Original
Location: BREATH
Disease Area: PALI
Partner / Member: MHH
Access-Number: 35163504

DZL Engagements

chevron-down